Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis

References

• Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 174–9
   PubMed Web of Science ®Google Scholar
• Cenac N, Coelho AM, Nauyen C, Compton S, Patricia AG, Wallace K, et al. Induction of intestinal inflammation in mouse by activation of protease-activated receptor-2. Am J Pathol 2002; 161: 1903–15
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Brezezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Parmacol Ther 2002; 16: 407–13
   PubMed Web of Science ®Google Scholar
• Yamada T, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 1992; 102: 1524–34
   PubMed Web of Science ®Google Scholar
• Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92: 420–3
   PubMed Web of Science ®Google Scholar
• Sendo T, Itoh Y, Goromaru T, Sumimura T, Saito M, Aki K, et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br J Pharmacol 2003; 138: 959–67
   PubMed Web of Science ®Google Scholar
• Sendo T, Sumimura T, Itoh Y, Goromaru T, Aki K, Yano T, et al. Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal 2003; 15: 773–81
   PubMed Web of Science ®Google Scholar
• Moriss GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795–803
   PubMed Web of Science ®Google Scholar
• Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979; 27: 1131–9
   PubMed Web of Science ®Google Scholar
• Walls AF, Jones DB, Williams JH, Church MK, Holgate ST. Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol 1990; 162: 119–26
   PubMed Web of Science ®Google Scholar
• Kojima R, Hamamoto S, Moriwaki M, Iwadate K, Ohwaki T. The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid. Folia Pharmacol Jpn 2001; 118: 123–30
   PubMedGoogle Scholar
• Yoshida N, Yoshikawa T, Yamaguchi T, Naito Y, Tanigawa T, Murase H, et al. A novel water-soluble vitamin E derived protects against experimental colitis in rats. Antioxid Redox Signal 1999; 1: 555–62
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351–8
   PubMed Web of Science ®Google Scholar
• Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984; 87: 1344–50
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol regent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Naito Y, Takagi T, Matsuyama K, Yoshida N, Yoshikawa T. Pioglitazone, a specific PPAR-γ ligand, inhibits aspirin-induced gastric mucosal injury in rats. Aliment Pharmacol Ther 2001; 15: 865–73
   PubMed Web of Science ®Google Scholar
• Tomatsuri N, Yoshida N, Takagi T, Katada K, Isozaki Y, Imamoto E, et al. Edaravone, a newly developed radical scavenger, protects ischemia-reperfusion injury of the small intestine in rats. Int J Mol Med 2004; 13: 105–9
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1984; 44: 643–52
   Web of Science ®Google Scholar
• Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990; 99: 119–24
   PubMed Web of Science ®Google Scholar
• Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999; 45: 210–7
   PubMed Web of Science ®Google Scholar
• Xu X, Weksler-Zangen S, Pikasky A, Pappo O, Wengrower D, Bischoff SC, et al. Mast cells involvement in the inflammation and fibrosis development of the TNBS induced rat model of colitis. Scand J Gastroenterol 2002; 37: 330–7
   PubMed Web of Science ®Google Scholar
• Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, et al. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology 2003; 125: 775–85
   PubMed Web of Science ®Google Scholar
• Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998; 274: G203–9
   PubMed Web of Science ®Google Scholar
• Stenton GR, Vliagoftis H, Befus D. Role of intestinal mast cells in modulating gastrointestinal pathophysiology. Ann Alllergy Asthma Immunol 1998; 81: 1–15
   PubMed Web of Science ®Google Scholar
• Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, et al. Pharmacological studies of FUT-175, nafamstat mesilate I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35: 203–27
   PubMedGoogle Scholar
• Temkin V, Kantor B, Weg V, Hartman ML, Schaffer FL. Tryptase activates the mitogen-activated protein kinase/active protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 2002; 169: 2662–9
   PubMed Web of Science ®Google Scholar
• O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene 2001; 20: 1570–81
   PubMed Web of Science ®Google Scholar
• Corvera CU, Dery K, McConalogue P, Gamp P, Thoma M, Al-Ani B, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through protease-activated receptors-1 and -2. J Physiol 1999; 517: 741–56
   PubMed Web of Science ®Google Scholar
• Shapacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, et al. Agonists of protease-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappa B in human dermal microvascular endothelial cells. J Invest Dermatol 2002; 118: 380–5
   PubMed Web of Science ®Google Scholar
• Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 2003; 9: 224–9
   PubMed Web of Science ®Google Scholar
• Harada K, Toyonaga A, Mitsuyama K, Sasaki E, Tanikawa K. Role of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in rat experimental colitis. Digestion 1994; 55: 179–84
   PubMed Web of Science ®Google Scholar
• Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344–67
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yamaguchi T, Kitazumi S, Takahasi S, Naito Y, Yoshikawa T, . Role of PMN and active oxygen species in the pathogenesis of TNBS-colitis in rats. Cytokines, cholera, and the gut, GT Keusch, M Kawakami, et al. IOS Press Ohmsha, TokyoJapan 1995; 131–5
   Google Scholar
• Segar LW, Gales BJ. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Clin Pharmacol 1992; 11: 514–28
   Google Scholar
• Perterson TC, Cleary CE, Shaw AM, Malatjalian DA, Zanten VV, et al. Therapeutic role for bismuth compounds in TNBS-induced colitis in rats. Dig Dis Sci 2000; 45: 466–73
   PubMed Web of Science ®Google Scholar
• Wallace JL, Macnaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29–36
   PubMed Web of Science ®Google Scholar
• Kennedy M, Wilson L, Szabo C, Salzman AL. 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 1999; 4: 437–43
   PubMed Web of Science ®Google Scholar